

CITATION REPORT

List of articles citing

Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients

DOI: 10.1016/s0735-1097(83)80226-5

Journal of the American College of Cardiology, 1983, 2, 806-17

Source: <https://exaly.com/paper-pdf/16409684/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
395	Ventricular Fibrillation II: Progress Report since 1971. 1984 , 2, 395-419		1
394	Torsade de pointes induced by N-acetylprocainamide. <i>Journal of the American College of Cardiology</i> , 1984 , 4, 621-4	15.1	78
393	Long QT: good, bad or indifferent?. <i>Journal of the American College of Cardiology</i> , 1984 , 4, 398-413	15.1	198
392	Ventricular tachyarrhythmias in the long QT syndromes. 1984 , 68, 1079-109		78
391	Diagnosis and treatment of arrhythmias during and following open heart surgery. 1984 , 68, 1153-69		21
390	Torsades de pointes due to n-acetylprocainamide. 1985 , 8, 528-31		12
389	Ventricular fibrillation. <i>Journal of the American College of Cardiology</i> , 1985 , 5, 43B-54B	15.1	56
388	Torsades de pointes. A clearly defined syndrome or an electrocardiographic curiosity?. 1985 , 7, 421-7		2
387	Torsades de pointes. 1985 , 3, 289-94		2
386	QT prolongation and arrhythmia suppression. 1985 , 109, 411-5		29
385	Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. 1986 , 111, 1088-93		432
384	Effects of quinidine versus procainamide on the QT interval. 1986 , 58, 512-6		13
383	Evaluation of the patient with congestive heart failure and ventricular arrhythmias. 1986 , 57, 19B-24B		4
382	Natural history of patients with congestive heart failure. Potential role of converting enzyme inhibitors in improving survival. <i>American Journal of Medicine</i> , 1986 , 81, 32-5	2.4	8
381	Polymorphous ventricular tachycardia and atrioventricular block. 1986 , 9, 522-6		30
380	Prolonged QT-Interval Syndromes. 1986 , 256, 2985		90
379	Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. <i>Circulation</i> , 1986 , 74, 340-9	16.7	149

378	Advances in the Management of Tachyarrhythmias. 1987 , 2, 65-75		2
377	Torsade de pointes during loading with amiodarone. <i>European Heart Journal</i> , 1987 , 8, 541-3	9.5	17
376	Treatment of torsades de pointes with esophageal atrial pacing. <i>American Journal of Medicine</i> , 1987 , 83, 971-2	2.4	3
375	Torsade de pointes during administration of pentamidine isethionate. <i>American Journal of Medicine</i> , 1987 , 83, 571-6	2.4	96
374	Torsades de pointes associated with drugs and toxins: recognition and management. 1987 , 113, 1470-82		113
373	Management of ventricular tachycardia. 1987 , 92, 157-60		
372	Analysis of ambulatory electrocardiograms in 14 patients who experienced sudden cardiac death during monitoring. 1987 , 10, 621-32		29
371	Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. 1987 , 59, 19E-25E		23
370	Proarrhythmic effects of antiarrhythmic drugs. 1987 , 59, 26E-31E		87
369	Torsades de pointes precipitated by a Chinese herbal remedy. 1987 , 60, 1186-7		14
368	Pharmacodynamics and pharmacokinetics of oral pirlmenol. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 42, 405-10	6.1	9
367	The electrocardiogram in anorexia nervosa. 1988 , 7, 791-795		1
366	Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 43, 636-42	6.1	51
365	A canine model of torsades de pointes. 1988 , 11, 2235-45		21
364	"Torsade de pointes". 1988 , 11, 2246-9		9
363	The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. 1988 , 31, 115-72		681
362	"Torsades de pointes" and atrioventricular block. 1988 , 11, 9-13		15
361	Role of plasma concentration monitoring in the evaluation of response to antiarrhythmic drugs. 1988 , 62, 9H-17H		11

360	Role of the electrocardiogram in determining electrophysiologic end points of drug therapy. 1988 , 62, 34H-38H		11
359	Overview of the clinical pharmacology of antiarrhythmic drugs. 1988 , 61, 61A-69A		17
358	Chronic ventricular arrhythmias: which drug for which patient?. 1988 , 61, 83A-94A		1
357	Reply. 1988 , 115, 1342		
356	Treatment of torsade de pointes with magnesium sulfate. <i>Circulation</i> , 1988 , 77, 392-7	16.7	466
355	Respective role of sympathetic tone and of cardiac pauses in the genesis of 62 cases of ventricular fibrillation recorded during Holter monitoring. <i>European Heart Journal</i> , 1988 , 9, 1276-83	9.5	103
354	Management of Arrhythmias in Heart Failure. 1989 , 7, 145-169		14
353	Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy. <i>Circulation</i> , 1989 , 80, 1063-9	16.7	70
352	A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?. 1989 , 4, 400-11		4
351	Ventricular tachycardia. 1989 , 12, 586-99		1
350	The proarrhythmic effects of amiodarone. 1989 , 31, 439-46		14
349	The efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. 1989 , 31, 319-54		29
348	Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine. 1989 , 18, 255-7		10
347	Polymorphic ventricular tachycardia. 1989 , 18, 100-2		3
346	Discrimination of retrograde from anterograde atrial activation using intracardiac electrogram waveform analysis. 1989 , 12, 1622-30		31
345	Quinidine-Induced Early Afterdepolarizations and Triggered Activity. 1989 , 3, 323-338		15
344	Torsade de pointes. 1989 , 118, 1359-60		
343	The role of silent ischemia, the arrhythmic substrate and the short-long sequence in the genesis of sudden cardiac death. <i>Journal of the American College of Cardiology</i> , 1989 , 14, 1618-25	15.1	71

342	Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations?. <i>Journal of the American College of Cardiology</i> , 1989 , 14, 172-84	15.1	227
341	Quinidine-induced long QTU interval and torsade de pointes: role of bradycardia-dependent early afterdepolarizations. <i>Journal of the American College of Cardiology</i> , 1989 , 14, 252-7	15.1	95
340	Proarrhythmia: a paradoxical response to antiarrhythmic agents. 1989 , 9, 144-53		8
339	Magnesium therapy in ventricular arrhythmias. 1990 , 13, 937-45		31
338	Torsade de pointes and T-U wave alternans associated with arsenic poisoning. 1990 , 13, 164-70		45
337	Sudden arrhythmic cardiac death--mechanisms, resuscitation and classification: the Seattle perspective. 1990 , 65, 4B-12B		142
336	Clinical features of arrhythmia aggravation by antiarrhythmic drugs and their implications for basic mechanisms. 1990 , 19, 153-172		14
335	Issues in the Treatment of Ventricular Ectopy: Past, Present, and Future Controversy. 1990 , 3, 283-294		1
334	Clinical spectrum of ventricular tachycardia. <i>Circulation</i> , 1990 , 82, 1561-73	16.7	82
333	Magnesium treatment of torsade de pointes--a case report. 1990 , 41, 577-81		3
332	Paradoxical effects of exercise on the QT interval in patients with polymorphic ventricular tachycardia receiving type Ia antiarrhythmic agents. <i>Circulation</i> , 1990 , 81, 14-9	16.7	201
331	Conduction velocity depression and drug-induced ventricular tachyarrhythmias. Effects of lidocaine in the intact canine heart. <i>Circulation</i> , 1990 , 81, 1024-38	16.7	48
330	Ventricular Tachyarrhythmias Related to Early Afterdepolarizations and Triggered Firing: Relationship to QT Interval Prolongation and Potential Therapeutic Role for Calcium Channel Blocking Agents. <i>Journal of Cardiovascular Electrophysiology</i> , 1990 , 1, 170-195	2.7	62
329	Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators. <i>Circulation</i> , 1990 , 82, 1362-9	16.7	92
328	Acute treatment of torsades de pointes with amiodarone: proarrhythmic and antiarrhythmic association of QT prolongation. 1990 , 119, 185-6		18
327	Facilitation of ventricular tachycardia initiation by procainamide during programmed ventricular stimulation in patients with heart failure. 1990 , 23, 77-83		3
326	Drug-induced torsades de pointes: role of early afterdepolarizations and dispersion of repolarization. <i>American Journal of Medicine</i> , 1990 , 89, 241-6	2.4	67
325	Torsades de Pointes: a review. 1991 , 9, 250-5		22

324	When is drug therapy warranted to prevent sudden cardiac death?. 1991 , 41 Suppl 2, 24-46		6
323	.		1
322	Suppression of Torsades de Pointes with verapamil in patients with atrio-ventricular block. <i>European Heart Journal</i> , 1991 , 12, 635-8	9.5	28
321	Electrophysiologic mechanisms for ventricular arrhythmias in left ventricular dysfunction: electrolytes, catecholamines and drugs. 1991 , 31, 1053-60		21
320	Sudden cardiac death while wearing a Holter monitor. 1991 , 67, 381-6		77
319	Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. 1991 , 67, 774-6		168
318	Effects of atrioventricular block on ventricular fibrillation threshold in dog. 1991 , 14, 583-6		
317	Bradycardia-dependent early afterdepolarizations in a patient with QTU prolongation and torsade de pointes in association with marked bradycardia and hypokalemia. 1991 , 14, 1105-11		36
316	Torsades de pointes: prevention and therapy. 1991 , 5, 509-13		19
315	QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. 1991 , 5, 515-30		67
314	Torsades de pointes and early afterdepolarizations. 1991 , 5, 531-7		29
313	Electrophysiologic mechanisms involved in the development of torsades de pointes. 1991 , 5, 203-12		16
312	Torsades de pointes therapy with phenytoin. 1991 , 20, 198-200		16
311	Reentrant ventricular arrhythmias in the late myocardial infarction period: mechanism by which a short-long-short cardiac sequence facilitates the induction of reentry. <i>Circulation</i> , 1991 , 83, 268-78	16.7	50
310	Antiarrhythmic drugs. 1991 , 31, 427-55		51
309	Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. 1991 , 10, 59-62		53
308	Relation between ventricular repolarization duration and cardiac cycle length during 24-hour Holter recordings. Findings in normal patients and patients with long QT syndrome. <i>Circulation</i> , 1992 , 85, 1816-21	16.7	147
307	Acquired long QT syndrome due to antiarrhythmic drugs and bradyarrhythmias. 1992 , 644, 57-73		12

306	Torsades de pointes and ventricular fibrillation in a canine model of quinidine-induced QT prolongation. 1992 , 644, 93-102		5
305	Torsade de pointes after inhaled pentamidine. 1992 , 21, 1403-5		16
304	Pharmacology of the class III antiarrhythmic agent sotalolol in patients with arrhythmias. 1992 , 69, 206-12		25
303	Current status of class III antiarrhythmic drug therapy. 1993 , 72, 44B-49B		77
302	Torsade de pointes. 1993 , 16, 683-6		88
301	Early after/depolarizations and triggered activity: mechanisms and autonomic regulation. 1993 , 7, 39-49		15
300	Another sudden death in a child treated with desipramine. 1993 , 32, 792-7		152
299	Drug effects on the electrocardiogram. A review of their clinical importance. 1993 , 46, 219-48		15
298	Refractory postoperative torsades de pointes syndrome successfully treated with isoproterenol. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1993 , 7, 210-2	2.1	7
297	Direct and autonomically mediated effects of oral quinidine on RR/QT relation after an abrupt increase in heart rate. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 99-105	15.1	84
296	Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular Drugs. 1993 , 270, 2590		539
295	Torsade de pointes associated with the use of intravenous haloperidol. 1993 , 119, 391-4		89
294	Evaluation and Management of Patients with Polymorphic Ventricular Tachycardia. 1993 , 11, 39-54		15
293	Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. <i>Circulation</i> , 1994 , 89, 413-22	16.7	125
292	Torsade de pointes and elevated magnesium and calcium requirements associated with intravenous pentamidine. 1994 , 9, 191-5		4
291	Risks and benefits of antiarrhythmic therapy. 1994 , 331, 785-91		101
290	Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. 1994 , 17, 197-202		27
289	Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs. <i>Journal of Cardiovascular Electrophysiology</i> , 1994 , 5, 408-11	2.7	10

288	Analysis of the initiation of spontaneous monomorphic ventricular tachycardia by stored intracardiac electrograms. <i>Journal of the American College of Cardiology</i> , 1994 , 23, 117-22	15.1	79
287	Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children. 1994 , 127, 64-70		48
286	Proarrhythmia: definition, risk factors, causes, treatment, and controversies. 1994 , 128, 575-85		30
285	Magnesium and its therapeutic uses: a review. <i>American Journal of Medicine</i> , 1994 , 96, 63-76	2.4	187
284	Cycle-length effects on the initiation of simulated torsade de pointes. 1994 , 27, 1-9		9
283	Subarachnoid hemorrhage: atypical presentation associated with rapidly changing cardiac arrhythmias. 1994 , 12, 370-3		11
282	Torsades de pointes induced by erythromycin and terfenadine. 1994 , 12, 636-8		46
281	Drug-induced torsade de pointes. Incidence, management and prevention. 1994 , 11, 463-76		62
280	Torsade de pointes. Mechanisms and management. 1994 , 47, 51-65		100
279	Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. 1994 , 105, 389-95		73
278	Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. 1995 , 122, 701-14		170
277	Increased propensity of women to develop torsades de pointes during complete heart block. <i>Journal of Cardiovascular Electrophysiology</i> , 1995 , 6, 1032-8	2.7	83
276	Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 1564-75	15.1	122
275	Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. <i>Journal of the American College of Cardiology</i> , 1995 , 26, 787-92	15.1	57
274	Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. 1996 , 131, 472-80		125
273	Mode of onset of torsade de pointes in congenital long QT syndrome. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 1262-8	15.1	131
272	Postextrasystolic U wave augmentation, a new marker of increased arrhythmic risk in patients without the long QT syndrome. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 1746-52	15.1	22
271	Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. 1996 , 78, 35-41		125

270	Electrophysiological findings in idiopathic recurrent ventricular fibrillation: special reference to mode of induction, drug testing, and long-term outcomes. 1996 , 19, 929-39		23
269	Temporary Cardiac Pacing in the Intensive Care Unit. 1996 , 11, 57-78		
268	The mode of onset of ventricular tachycardia. A patient-specific phenomenon. <i>European Heart Journal</i> , 1997 , 18, 1956-65	9.5	35
267	Current concepts in cardiopulmonary resuscitation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1997 , 11, 391-407	2.1	3
266	Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes. 1997 , 20, 695-705		27
265	Mechanisms in adrenergic dependent onset of torsades de pointes. 1997 , 20, 88-94		13
264	Changes in repolarization dynamicity and the assessment of the arrhythmic risk. 1997 , 20, 2614-24		44
263	Does subclinical hypothyroidism explain the increased susceptibility of women to torsades de pointes?. 1997 , 79, 963-5		7
262	A practical approach to torsade de pointes. 1997 , 20, 285-90		87
261	Polymorphic Ventricular Tachycardia: Primary Prevention, Immediate Evaluation & Management, Long-Term Management, and Experimental & Theoretical Developments. 1997 , 1, 116-122		
260	Adverse effects of amiodarone. 1998 , 21, 108-20		53
259	Abolition of drug-induced early afterdepolarizations by potassium channel activators in guinea-pig Purkinje fibres. 1998 , 25, 225-30		3
258	Acceleration-induced action potential prolongation and early afterdepolarizations. <i>Journal of Cardiovascular Electrophysiology</i> , 1998 , 9, 934-48	2.7	106
257	Early Electrocardiographic Signs of Drug-Induced Torsades de Pointes. <i>Annals of Noninvasive Electrocardiology</i> , 1998 , 3, 252-260	1.5	4
256	Proarrhythmia. 1998 , 82, 50N-58N		55
255	Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: classification, differential diagnosis, and implications for therapy. 1998 , 41, 17-34		78
254	Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. 1998 , 62, 2159-69		9
253	Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 169-76	15.1	68

252	Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. <i>Heart</i> , 1999 , 82, 319-24	5.1	54
251	Arrhythmogenic mechanisms of non-sedating antihistamines. 1999 , 29 Suppl 3, 174-81		52
250	Management of intermittent atrial fibrillation: drugs to maintain sinus rhythm. <i>Journal of Cardiovascular Electrophysiology</i> , 1999 , 10, 433-41	2.7	3
249	Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist. <i>Journal of Cardiovascular Electrophysiology</i> , 1999 , 10, 472-81	2.7	18
248	Torsades de Pointes. 1999 , 1, 187-195		12
247	Torsades de pointes: a case with multiple variables. 1999 , 17, 80-5		21
246	Long QT syndromes and torsade de pointes. 1999 , 354, 1625-33		542
245	Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 1415-23 ¹⁵¹		63
244	Sustained QT prolongation induced by tacrolimus in guinea pigs. 1999 , 65, PL197-202		15
243	Drug-induced torsade de pointes: from molecular biology to bedside. <i>The Japanese Journal of Pharmacology</i> , 2000 , 83, 1-19		90
242	D0870, an antifungal agent, induces reverse use-dependent QT prolongation in dogs. 2000 , 62, 491-7		2
241	Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. <i>Journal of Cardiovascular Electrophysiology</i> , 2000 , 11, 290-304	2.7	139
240	Intravenous magnesium for the treatment of cardiac arrhythmias. 2000 , 30, 54-60		5
239	Inappropriate pacing due to autoperpetuation of the ventricular rate stabilization algorithm: a manifestation of T wave oversensing by ICDs. 2000 , 23, 1446-7		10
238	Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. <i>Journal of Cardiovascular Electrophysiology</i> , 2000 , 11, 593-600	2.7	89
237	Analysis of the pattern of initiation of sustained ventricular arrhythmias in patients with implantable defibrillators. <i>Journal of Cardiovascular Electrophysiology</i> , 2000 , 11, 719-26	2.7	47
236	Initiation of spontaneous ventricular tachycardia: from spark to fire. <i>Journal of Cardiovascular Electrophysiology</i> , 2000 , 11, 727-9	2.7	7
235	Analysis of intracardiac electrograms showing monomorphic ventricular tachycardia in patients with implantable cardioverter-defibrillators. 2000 , 85, 580-7		49

234	Rate smoothing with cardiac pacing for preventing torsade de pointes. 2000 , 86, 111K-115K		27
233	Prevention of ventricular arrhythmias in the congenital long QT syndrome. 2000 , 2, 492-7		18
232	Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. 2000 , 47, 251-4		51
231	The pause that refreshes, or does it? Mechanisms in torsades de pointes. 2000 , 84, 235-7		29
230	The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. <i>European Heart Journal</i> , 2000 , 21, 1216-31	9.5	286
229	Amiodarone-induced AV block and ventricular standstill. A forme fruste of an idiopathic long QT syndrome. 2000 , 75, 105-8		20
228	Drug interactions with cisapride: clinical implications. 2000 , 39, 49-75		96
227	Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. 2001 , 24, 323-51		212
226	Electrophysiologic characteristics in initiation of paroxysmal atrial fibrillation from a focal area. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1658-64	15.1	36
225	Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1168-74	15.1	70
224	The QT interval?. 2001 , 43, 1-45		30
223	Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. 2001 , 85, 321-41		83
222	Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications. 2001 , 3, 613-27		32
221	Cardiovascular side effects of novel antipsychotics. 2001 , 6, 912-8		7
220	Torsade de pointes induced by ajmaline. 2001 , 90, 586-90		9
219	[Transmural ERP-dispersion from epi-, mid-and endomyocardium in healthy and hypertrophied dog myocardium]. 2001 , 21, 89-92		
218	Modulation of QT interval by cardiac sympathetic nerve sprouting and the mechanisms of ventricular arrhythmia in a canine model of sudden cardiac death. <i>Journal of Cardiovascular Electrophysiology</i> , 2001 , 12, 1068-73	2.7	71
217	Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias. 2001 , 92, 109-22		53

216	Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. 2001 , 21, 871-83	29
215	Assessment of the pro-arrhythmic potential of anti-arrhythmic drugs: an experimental approach. 2001 , 6, 89-97	14
214	Clinical aspects of ventricular arrhythmias associated with QT prolongation. 2001 , 3, K81-K88	16
213	Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. 2002 , 62, 1649-71	301
212	Probable case of torsades de pointes induced by fluconazole. 2002 , 22, 1632-7	32
211	What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. 2002 , 25, 1612-5	43
210	Physician-induced torsade de pointes--therapeutic implications. 2002 , 16, 101-9	11
209	Effectiveness of ibutilide in cardioversion of persistent atrial fibrillation in patients with dual chamber stimulation. 2003 , 9, 15-20	2
208	Prevention of sustained ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators-the PREVENT study. 2003 , 9, 383-9	29
207	Beat-to-beat assessment of QT/RR interval ratio in severe heart failure and overt myocardial ischemia: a measure of electrical integrity in diseased hearts. 2003 , 26, 836-42	12
206	Ziprasidone in the management of schizophrenia : the QT interval issue in context. 2003 , 17, 423-30	127
205	What clinicians should know about the QT interval. 2003 , 289, 2120-7	405
204	Proarrhythmic effect of pacemaker stimulation in patients with implanted cardioverter-defibrillators. <i>Circulation</i> , 2003 , 108, 192-7	16.7 57
203	Dual rate-dependent cardiac electrophysiologic effects of haloperidol: slowing of intraventricular conduction and lengthening of repolarization. 2003 , 41, 870-9	9
202	Long-short sequence may predict immediate recurrence of atrial fibrillation after external cardioversion. 2003 , 5, 11-6	9
201	T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. 2003 , 105, 671-6	232
200	. 2004 ,	23
199	Introduction. 1-7	

198	Acquired Long QT Syndrome Secondary to Noncardiac Conditions. 171-181		1
197	. 2004,		16
196	Perspective on Drug-induced Repolarization Changes. 182-190		
195	Dynamics of Acquired Long QT Syndrome. 406-416		
194	Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. 2004 , 9 Suppl 1, S65-83		104
193	Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome. <i>European Heart Journal</i> , 2004 , 25, 2149-54	9.5	60
192	Dynamics of T-U wave in patients with idiopathic ventricular tachycardia originating from the right ventricular outflow tract. 2004 , 27, 148-55		9
191	Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem?. 2004 , 37 Suppl, 15-24		85
190	Pro- and antiarrhythmic effects of fast cardiac pacing in a canine model of acquired long QT syndrome. 2004 , 369, 447-54		3
189	QT prolongation with antimicrobial agents: understanding the significance. 2004 , 64, 1091-124		91
188	Drug-induced prolongation of the QT interval. 2004 , 350, 1013-22		1513
187	Torsade de pointes: the clinical considerations. 2004 , 96, 1-6		77
186	Mechanisms of Acquired QT Prolongation and Torsades de Pointes. 8-23		
185	Perioperative and intraoperative pain and anesthetic care of the chronic pain and cancer pain patient receiving chronic opioid therapy. 2005 , 5, 18-32		27
184	A survey of health care practitioners knowledge of the QT interval. 2005 , 20, 392-6		28
183	Anti-Arrhythmic Drugs and Cardiac Resuscitation. 2005 , 351-376		
182	Male/female differences in pharmacology: safety issues with QT-prolonging drugs. 2005 , 14, 47-52		14
181	Detection of drug-induced proarrhythmia: balancing preclinical and clinical studies. <i>Heart Rhythm</i> , 2005 , 2, 773-6	6.7	8

180	Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. <i>Heart Rhythm</i> , 2005 , 2, 758-726.7	163
179	Cardiac Safety of Noncardiac Drugs. 2005 ,	8
178	Pacing for prevention of ventricular arrhythmias: time for a pause. <i>Heart Rhythm</i> , 2006 , 3, 581-2	6.7
177	Effects of a rate smoothing algorithm for prevention of ventricular arrhythmias: results of the Ventricular Arrhythmia Suppression Trial (VAST). <i>Heart Rhythm</i> , 2006 , 3, 573-80	6.7 23
176	Vulnerable window for conduction block in a one-dimensional cable of cardiac cells, 2: multiple extrasystoles. 2006 , 91, 805-15	25
175	Long QT and ST-T change associated with organophosphate exposure by aerial spray. 2006 , 22, 40-5	17
174	Torsades de pointes induced by antibiotics. 2006 , 17, 254-9	28
173	Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. 2006 , 49, 463-70	19
172	Modelling and imaging cardiac repolarization abnormalities. 2006 , 259, 91-106	11
171	Long QT syndrome: reduced repolarization reserve and the genetic link. 2006 , 259, 59-69	254
170	Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. 2006 , 101, 1333-8	47
169	What is drug-induced long QT and what is a potential clinical consequence?. 2006 , 21, 104-5	
168	Proarrhythmia. <i>Handbook of Experimental Pharmacology</i> , 2006 , 73-97	3.2 29
167	Computational biology in the study of cardiac ion channels and cell electrophysiology. 2006 , 39, 57-116	197
166	Analysis of terminal arrhythmias stored in the memory of pacemakers from patients dying suddenly. 2007 , 9, 380-4	15
165	QT prolongation and safety in the Indian population. 2007 , 2, 200-3	
164	Vulnerability to re-entry in simulated two-dimensional cardiac tissue: effects of electrical restitution and stimulation sequence. 2007 , 17, 043115	14
163	Moxifloxacin and torsade de pointes. 2007 , 41, 336-40	36

162	QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. 2007 , 18, 493-8		27
161	Drug-induced long QT and torsade de pointes: recent advances. 2007 , 22, 39-43		169
160	Considerations in the Diagnosis and Treatment of Arrhythmias in Patients with End-Stage Renal Disease. 2007 , 2, 31-37		6
159	Cardiovascular effects of antipsychotics. 2007 , 7, 829-39		46
158	Proarrhythmic effect of altered ventricular activation sequence in patients with permanent pacemaker. <i>Heart Rhythm</i> , 2007 , 4, 1487-8	6.7	2
157	Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia?. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 614-22	15.1	115
156	. 2007 ,		2
155	The Long QT Syndrome. 83-110		
154	Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. 2007 , 6, 904-16		294
153	Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user. 2007 , 62, 952-5		22
152	Is acquired short QT due to digitalis intoxication responsible for malignant ventricular arrhythmias?. 2007 , 40, 43-6		29
151	QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine. 2007 , 3, 178-81		28
150	Mechanisms of ventricular fibrillation initiation in MADIT II patients with implantable cardioverter defibrillators. 2008 , 31, 144-50		22
149	Prolonged Asymptomatic Torsade de Pointes. <i>Journal of Cardiovascular Electrophysiology</i> , 2008 , 2, 46-48 _{2.7}		0
148	The diagnosis and management of cardiovascular disease in cancer patients. 2008 , 33, 163-96		48
147	Understanding drug-induced torsades de pointes: a genetic stance. 2008 , 7, 231-9		11
146	Chronic methadone therapy complicated by torsades de pointes: a case report. 2008 , 34, 287-90		19
145	Torsade de Pointes, Ventricular Fibrillation, and Differential Diagnosis of Wide QRS Tachycardias. 2008 , 440-455		

144	In a swine model, chest compressions cause ventricular capture and, by means of a long-short sequence, ventricular fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2008 , 1, 282-9	6.4	13
143	Sensitivity of T-wave morphology and the QT interval to small drug-induced electrocardiographic changes. 2008 ,		0
142	QTc prolongation assessment in anticancer drug development: clinical and methodological issues. 2009 , 3, 130		8
141	Short-long sequences prior to ventricular tachycardia onset: analysis of VAST trial electrograms. <i>Journal of Cardiovascular Electrophysiology</i> , 2009 , 20, 545-50	2.7	5
140	Presenting rhythm in sudden deaths temporally proximate to discharge of TASER conducted electrical weapons. 2009 , 16, 726-39		48
139	Clinical importance of short-long-short sequences: analysing the mode of onset of ventricular tachycardias and atrial fibrillation. 2009 , 137, 177-80		1
138	Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology. 2009 , 32, 599-611		43
137	Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 88, 88-94	6.1	22
136	Sevoflurane and QTc Prolongation: An Interesting Observation, or a Clinically Significant Finding?. 2010 , 113, 772-5		10
135	Influence of extracellular K ⁺ concentrations on quinidine-induced K ⁺ current inhibition in rat ventricular myocytes. 2000 , 52, 99-105		9
134	Drug-induced long QT syndrome. 2010 , 62, 760-81		296
133	High-rate pacing reduces variability of repolarization and prevents repolarization-dependent arrhythmias in dogs with chronic AV block. <i>Journal of Cardiovascular Electrophysiology</i> , 2010 , 21, 1384-91 ^{2.7}		21
132	Levofloxacin and Torsades de Pointes. 2010 , 69, 474		0
131	Drug-induced arrhythmia. <i>Circulation</i> , 2010 , 122, 1426-35	16.7	75
130	Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. <i>Circulation</i> , 2010 , 121, 1047-60	16.7	372
129	Chest compressions cause recurrence of ventricular fibrillation after the first successful conversion by defibrillation in out-of-hospital cardiac arrest. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010 , 3, 72-8	6.4	49
128	Cardiovascular drugs inducing QT prolongation: facts and evidence. 2010 , 5, 65-72		18
127	Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 934-47	15.1	255

126	Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. 2010 , 70, 573-603		52
125	Focal and Reentrant Mechanisms of Torsades de Pointes: EAD, Reentry, or Chimera?. 2011 , 27, 28-37		3
124	Heart Rate and Rhythm. 2011 ,		4
123	QT Prolongation Is a Poor Predictor of Proarrhythmia Liability: Beyond QT Prolongation!. 2011 , 639-654		
122	The site of origin of torsade de pointes. <i>Heart</i> , 2011 , 97, 1650-4	5.1	16
121	Clinical and genetic determinants of torsade de pointes risk. <i>Circulation</i> , 2012 , 125, 1684-94	16.7	61
120	Ventricular Tachycardia Precipitated by Short-long-short Sequence in a Patient with Implantable-cardioverter Defibrillator. 2012 , 12, 24-6		2
119	Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. 2012 , 17, 102-9		15
118	Mechanisms Underlying Arrhythmogenesis in Long QT Syndrome. 2012 , 4, 17-27		6
117	Effect of chest compressions on ventricular activation. 2012 , 109, 670-4		11
116	Ventricular arrhythmias: state of the art. 2013 , 31, 595-605, ix		13
115	Clinical Pharmacology of Antiarrhythmic Drugs. 2013 , 343-364		2
114	Apamin induces early afterdepolarizations and torsades de pointes ventricular arrhythmia from failing rabbit ventricles exhibiting secondary rises in intracellular calcium. <i>Heart Rhythm</i> , 2013 , 10, 1516-24	6.7	57
113	Electrocardiographic implications of the prolonged QT interval. 2013 , 31, 866-71		7
112	Bradycardia alters Ca(2+) dynamics enhancing dispersion of repolarization and arrhythmia risk. 2013 , 304, H848-60		21
111	Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening. <i>Circulation Research</i> , 2013 , 113, e50-e61	15.7	64
110	The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. <i>European Heart Journal</i> , 2013 , 34, 1958-63	9.5	21
109	Importance of QT interval in clinical practice. 2014 , 55, 607-11; quiz 612		10

108	QT interval in healthy dogs: which method of correcting the QT interval in dogs is appropriate for use in small animal clinics?. 2014 , 34, 469-472		4
107	QT interval prolongation in end-stage liver disease cannot be explained by nonhepatic factors. <i>Annals of Noninvasive Electrocardiology</i> , 2014 , 19, 574-81	1.5	6
106	Reduction of ICD shock burden by eliminating back-up pacing induced ventricular tachyarrhythmias. <i>Journal of Cardiovascular Electrophysiology</i> , 2014 , 25, 889-895	2.7	4
105	Quetiapine and the need for a thorough QT/QTc study. 2014 , 34, 3-6		23
104	Prolongation of a prolonged QT: a case of an undiagnosed congenital long QT syndrome. 2014 , 174, 1831-3		0
103	Risk screening for long QT prior to prescribing levofloxacin. 2014 , 32, 1153.e1-3		2
102	Nonlinear and Stochastic Dynamics in the Heart. 2014 , 543, 61-162		121
101	Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. 2014 , 16, 101-8		108
100	EHRA/HRS/APHS expert consensus on ventricular arrhythmias. <i>Heart Rhythm</i> , 2014 , 11, e166-96	6.7	179
99	EHRA/HRS/APHS expert consensus on ventricular arrhythmias. 2014 , 30, 327-349		3
98	EHRA/HRS/APHS expert consensus on ventricular arrhythmias. 2014 , 16, 1257-83		135
97	Call "the Cleaners": How to Treat Drug-Induced Torsades de Pointes. 2015 , 1, 323-325		0
96	Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures. 2015 , 1, 315-322		38
95	Interventricular dispersion in repolarization causes bifid T waves in dogs with dofetilide-induced long QT syndrome. <i>Heart Rhythm</i> , 2015 , 12, 1343-51	6.7	10
94	Sudden Cardiac Death and Disorders of the QT Interval: Anesthetic Implications and Focus on Perioperative Management. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015 , 29, 1723-33	2.1	13
93	Further refinement of torsades de pointes. <i>Heart Rhythm</i> , 2015 , 12, 506-507	6.7	
92	Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1639-1650	15.1	152
91	Disturbances of cardiac wavelength and repolarization precede Torsade de Pointes and ventricular fibrillation in Langendorff perfused rabbit hearts. <i>Progress in Biophysics and Molecular Biology</i> , 2016 , 121, 3-10	4.7	6

90	A Tale of 2 Diseases: The History of Long-QT Syndrome and Brugada Syndrome. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 100-8	15.1	34
89	Atrioventricular block and pause-dependent torsade de pointes. <i>HeartRhythm Case Reports</i> , 2017 , 3, 115-119	1	3
88	The association between pro-arrhythmic agents and aortic stenosis in young adults: is it sufficient to clarify the sudden unexpected deaths?. <i>Cardiology in the Young</i> , 2017 , 27, 929-935	1	2
87	Pacemaker troubleshooting and follow-up. 2017 , 231-251		
86	Sudden cardiac death in a dog during Holter recording-R on T phenomenon. <i>Journal of Veterinary Cardiology</i> , 2017 , 19, 455-461	1.9	8
85	Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. <i>BMJ Open</i> , 2017 , 7, e016627	3	27
84	Role of abnormal repolarization in the mechanism of cardiac arrhythmia. <i>Acta Physiologica</i> , 2017 , 220 Suppl 712, 1-71	5.6	14
83	Association of Serum Magnesium on Mortality in Patients Admitted to the Intensive Cardiac Care Unit. <i>American Journal of Medicine</i> , 2017 , 130, 229.e5-229.e13	2.4	33
82	Influence of long-term oral application of quinolones on the ECG curve in dogs. <i>Polish Journal of Veterinary Sciences</i> , 2017 , 20, 567-572	0.7	0
81	. 2017 ,		
80	Novel Two-Step Classifier for Torsades de Pointes Risk Stratification from Direct Features. <i>Frontiers in Pharmacology</i> , 2017 , 8, 816	5.6	24
79	Recent heart rate history affects QT interval duration in atrial fibrillation. <i>PLoS ONE</i> , 2017 , 12, e01729623.7		4
78	Premature ventricular contraction-induced polymorphic ventricular tachycardia after leadless pacemaker implantation: A unique adverse effect of leadless pacing. <i>HeartRhythm Case Reports</i> , 2018 , 4, 180-183	1	8
77	Quantitative Understanding of QTc Prolongation and Gender as Risk Factors for Torsade de Pointes. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 304-309	6.1	13
76	Perioperative management of patients with congenital or acquired disorders of the QT interval. <i>British Journal of Anaesthesia</i> , 2018 , 120, 629-644	5.4	16
75	Deleterious protein-altering mutations in the SCN10A voltage-gated sodium channel gene are associated with prolonged QT. <i>Clinical Genetics</i> , 2018 , 93, 741-751	4	6
74	Comparison of the origin and coupling interval between ectopy with and without atrial fibrillation initiation. <i>Journal of Cardiology</i> , 2018 , 71, 59-64	3	7
73	Iatrogenic QT Prolongation. 2018 , 383-418		

72	Discordant Alternans as a Mechanism for Initiation of Ventricular Fibrillation In Vitro. <i>Journal of the American Heart Association</i> , 2018 , 7, e007898	6	6
71	Distinct Occurrence of Proarrhythmic Afterdepolarizations in Atrial Versus Ventricular Cardiomyocytes: Implications for Translational Research on Atrial Arrhythmia. <i>Frontiers in Pharmacology</i> , 2018 , 9, 933	5.6	3
70	Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty. <i>Therapeutic Advances in Drug Safety</i> , 2018 , 9, 475-493	3.5	10
69	Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease. <i>Circulation</i> , 2019 , 139, 2304-2314	16.7	25
68	Scaling and correlation properties of RR and QT intervals at the cellular level. <i>Scientific Reports</i> , 2019 , 9, 3651	4.9	5
67	R-From-T as a Common Mechanism of Arrhythmia Initiation in Long QT Syndromes. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019 , 12, e007571	6.4	15
66	Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019 , 96, 15-26	1.7	6
65	Ventricular storm following late presentation acute myocardial infarction. <i>Heart</i> , 2020 , 106, 1399-1448	5.1	
64	QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. <i>Heart Rhythm</i> , 2020 , 17, 1425-1433	6.7	176
63	Mechanism of spontaneous initiation of ventricular fibrillation in patients with implantable defibrillators. <i>Journal of Cardiovascular Electrophysiology</i> , 2020 , 31, 2415-2424	2.7	
62	Polymorphic ventricular tachycardia, ischaemic ventricular fibrillation, and torsade de pointes: importance of the QT and the coupling interval in the differential diagnosis. <i>European Heart Journal</i> , 2021 , 42, 3965-3975	9.5	10
61	Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry. <i>European Heart Journal</i> , 2021 , 42, 2827-2838	8.5	18
60	Polymorphic Ventricular Tachycardia: Terminology, Mechanism, Diagnosis, and Emergency Therapy. <i>Circulation</i> , 2021 , 144, 823-839	16.7	3
59	Torsade de pointes: A nested case-control study in an integrated healthcare delivery system. <i>Annals of Noninvasive Electrocardiology</i> , 2021 , e12888	1.5	1
58	Ventricular arrhythmias in the young: clinical and experimental findings. <i>Developments in Cardiovascular Medicine</i> , 1987 , 134-152		0
57	Drug-induced torsades de pointes: clinical and experimental observations bearing on mechanism. <i>Developments in Cardiovascular Medicine</i> , 1987 , 164-182		2
56	Mechanisms of sudden death during Holter monitoring: A study of 74 cases. <i>Developments in Cardiovascular Medicine</i> , 1987 , 183-202		1
55	Drugs after Cardioversion to Prevent Relapses of Chronic Atrial Fibrillation or Flutter. <i>Developments in Cardiovascular Medicine</i> , 1992 , 105-148		6

54	Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. 2000 , 569-581		1
53	Drug-induced Channelopathies. 2004 , 151-157		4
52	Iatrogenic QT Prolongation. 2010 , 365-402		2
51	Cardiac effects of anticholinesterase agents. 1992 , 135-144		0
50	Clinical Pharmacology of Antiarrhythmic Drugs. 2007 , 433-446		1
49	Drug-Induced Torsade de Pointes: From Molecular Biology to Bedside. <i>The Japanese Journal of Pharmacology</i> , 2000 , 83, 1-19		10
48	Case report: pentamidine and polymorphic ventricular tachycardia revisited. <i>American Journal of the Medical Sciences</i> , 1993 , 305, 236-40	2.2	16
47	QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin.		19
46	Prolonged Asymptomatic Torsade de Pointes. <i>Journal of Cardiovascular Electrophysiology</i> , 1988 , 2, 46-48.		1
45	QT Prolongation with Quinolone Antimicrobial Agents. 421-440		1
44	Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. <i>Circulation</i> , 1995 , 91, 864-72	16.7	127
43	Sex difference in risk of torsade de pointes with d,l-sotalol. <i>Circulation</i> , 1996 , 94, 2535-41	16.7	319
42	The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. <i>Circulation Research</i> , 1996 , 79, 474-92	15.7	267
41	Genetics of acquired long QT syndrome. <i>Journal of Clinical Investigation</i> , 2005 , 115, 2025-32	15.9	169
40	Influence of Chest Compressions on Circulation during the Peri-Cardiac Arrest Period in Porcine Models. <i>PLoS ONE</i> , 2016 , 11, e0155212	3.7	3
39	Mechanisms of drug-induced proarrhythmia in clinical practice. <i>World Journal of Cardiology</i> , 2013 , 5, 175-85		22
38	Methadone prolongs cardiac conduction in young patients with cancer-related pain. <i>Journal of Opioid Management</i> , 2016 , 12, 131-8	0.8	28
37	Acquired abnormal QT prolongation and torsade de pointes [Clinical significance of genetic information from congenital long QT syndrome. 2000 , 99-111		21

- 36 Polymorphic Ventricular Tachycardia and Long QT Syndromes. **2000**, 731-761
- 35 The Genetics of Cardiac Channelopathies: Implications for Therapeutics. *Handbook of Experimental Pharmacology*, **2004**, 223-241 3,2
- 34 Cardiopulmonary Resuscitation: Basic and Advanced Life Support. **2010**, 2971-3001
- 33 The QT Interval. **2010**, 833-862 1
- 32 The QT Interval. **2012**, 351-380
- 31 Ventrikuläre Arrhythmien im Alter [Therapeutische Überlegungen]. **1984**, 134-151
- 30 The arrhythmogenic effects of antiarrhythmic drugs. Types, mechanisms and predisposing factors. **1988**, 301-310
- 29 Lessons from recordings of sudden death by Holter monitoring. *Developments in Cardiovascular Medicine*, **1991**, 99-111 1
- 28 Cardiac Arrhythmias: Premature Beats and Paroxysmal Tachycardias. **1991**, 349-374
- 27 Klinischer Teil. **1992**, 132-341
- 26 Klinischer Teil. **1996**, 141-369
- 25 Managing paroxysmal atrial tachycardias in patients with pacemakers. *Developments in Cardiovascular Medicine*, **1996**, 167-173
- 24 Drug-Induced Prolongation of the QT Interval: Present and Future Challenges for Drug Discovery. **2015**, 1039-1057
- 23 Proarrhythmic Effects of Antiarrhythmic and Non-antiarrhythmic Drugs. **2015**, 1015-1038
- 22 Toxicant-Induced Torsade de Pointes. **2016**, 1-10
- 21 Toxicant-Induced Torsade de Pointes. **2017**, 509-518
- 20 Cardiac Arrhythmia and Device Management in Patients with Cancer. **2018**, 175-182
- 19 VENTRICULAR TACHYARRHYTHMIA IN FALCIPARUM MALARIA. *Journal of Evidence Based Medicine and Healthcare*, **2018**, 5, 1571-1576 0

18	Drug-Induced Long QT Syndrome and Torsades de Pointes. 2020 , 185-200		1
17	"Ryanopathies" and RyR2 dysfunctions: can we further decipher them using in vitro human disease models?. <i>Cell Death and Disease</i> , 2021 , 12, 1041	9.8	1
16	Arritmogēnesis de las secuencias corto-largo-corto. <i>REC: CardioClinics</i> , 2020 , 55, 53-55	0.2	
15	Class I Antiarrhythmic Drugs: Na ⁺ Channel Blockers. 2020 , 31-105		0
14	Top 20 drug - drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients. <i>Journal of Family Medicine and Primary Care</i> , 2020 , 9, 6023-6040	1.5	0
13	Cellular, Molecular, and Pharmacologic Mechanisms Underlying Drug-Induced Cardiac Arrhythmogenesis. 2005 , 37-66		
12	Drug-induced long qt syndrome. <i>Journal of Arrhythmology</i> , 2020 , 27, 42-52	0.3	0
11	Ventricular arrhythmias. <i>Cmaj</i> , 1988 , 138, 903-13	3.5	1
10	Should class III drugs be initiated in hospital to prevent drug-induced torsade de pointes arrhythmias?. <i>Netherlands Heart Journal</i> , 2003 , 11, 70-76	2.2	
9	Survival of a Newborn with 2:1 Atrioventricular Block, Long QT Syndrome, and Torsades de Pointes. <i>Ochsner Journal</i> , 2007 , 7, 181-4	1.5	2
8	Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2021 , 15, 17539447211058892	3.4	0
7	Traditional risk factors for QT interval prolongation and torsades de pointes. 2022 , 79-111		
6	Overview of torsades de pointes. 2022 , 1-26		
5	Drug-induced torsades de pointes. 2022 , 39-50		
4	Role of Drugs in Torsade de Pointes and Triggered Activity. 1995 , 251-289		0
3	Long QT begets long QT.		0
2	Adverse reactions to antiarrhythmic drugs.		0
1	Plötzlicher Herztod nach Kardioversion.		0

